🔗 Visit the ClinicalTrials.gov page for NCT00821652
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. | Oncoimmunology | 2012 | 1.88 |
| 2 | Trial watch: Peptide vaccines in cancer therapy. | Oncoimmunology | 2012 | 1.17 |
| 3 | Trial Watch: Peptide-based anticancer vaccines. | Oncoimmunology | 2015 | 1.13 |
| 4 | The Expression of Toll-like Receptors in Dermatological Diseases and the Therapeutic Effect of Current and Newer Topical Toll-like Receptor Modulators. | J Clin Aesthet Dermatol | 2010 | 0.91 |
| 5 | The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. | Expert Rev Clin Pharmacol | 2011 | 0.88 |
| 6 | Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. | Oncoimmunology | 2015 | 0.85 |
| 7 | Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma. | Cancer Immunol Res | 2015 | 0.78 |
| 8 | Cancer testis antigen and immunotherapy. | Immunotargets Ther | 2013 | 0.76 |